Ask AI
ProCE Banner Activity

A New Paradigm in IgAN Management—Advancing Clinical Practice in the Era of Therapeutic Expansion

Slideset

Expert-curated slides on the latest advances in diagnosing and managing patients with IgA nephropathy (IgAN), including the current data on new and emerging IgAN therapies.

Released: December 03, 2025

Share

Provided by

Provided by Clinical Care Options, LLC, in partnership with the American Kidney Fund (AKF).

ProCE Banner

Supporters

Supported by independent educational grants from Novartis Pharmaceuticals Corporation and Vertex Pharmaceuticals Incorporated.

Novartis Pharmaceuticals Corporation

Vertex Pharmaceuticals Incorporated

Partners

American Kidney Fund

ProCE Banner

Target Audience

This educational activity is intended for nephrology physicians, nurse practitioners, physician associates, and other healthcare professionals who care for patients with IgAN.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Differentiate the mechanistic targets of novel therapies for IgAN, including those that modulate the complement pathway, endothelin system, APRIL, and dual APRIL/BAFF signaling

  • Assess the most recent clinical efficacy and safety data on emerging IgAN therapies to support personalized treatment decisions

  • Implement patient-centered strategies incorporating novel IgAN treatments to slow disease progression and optimize long-term outcomes